Industry Spotlight: Linus Biotechnology

About Linus Biotechnology

Linus Biotechnology is a patient-centric, breakthrough science precision exposome medicine company whose mission is to improve human health through environmental biodynamics.

Its precision exposome medicine program follows the evolving precision medicine paradigm of: patient group stratification, disease & patient phenotyping; biomarker & diagnostics, patient-journey monitoring; characterization of pathways and biological mechanisms for target discovery; drug development and clinical-trial design.

In addition to its work in the field of autism, Linusbio plans to develop breakthrough programs for Amyotrophic Lateral Sclerosis (ALS), Inflammatory Bowel Disease (IBD), Attention Deficit Hyperactive Disorder (ADHD), Psychosis/schizophrenia, Renal disease and pediatric cancer

StrandDx-ASD – diagnostic tool for autism

StrandDx-ASD diagnostic aid is based on novel molecular biomarkers established using Linus Biotechnology’s proprietary exposome and biological response sequencing platform.

StrandDx-ASD has been awarded breakthrough designation by the FDA. Presently Linusbio is working closely with the FDA for full approval in the United States.

For more information visit Linusbio website.

Manish Arora, Linus Biotechnology CEO at BRAIN Synchrony Symposium